Another promising NK cell-focused bispecific platform is developed by AvidBiotics to target tumors that evade NK killing via downregulation or shedding of the NKG2D ligand MICA, which is a major limiting step in NK-mediated tumor targeting. Here, MICA is linked to neoplasm.